Summary
A total of 40 patients with metastatic breast cancer were treated with 120 mg/m2 i.v. epirubicin every 3 weeks for a maximum of 10 cycles. Nine achieved a complete response and 17 showed a partial response, for an objective response rate of 65% (95% confidence interval, 47%–83%); the median duration of response was 7 months (range, 1–15 months) and median survival amounted to 13 months (range, 2–20 months). Leucopenia (grade 2 or 3) was seen in 14 patients on day 21 of the cycle. A subset of nine patients underwent blood counts on day 10, when all had marked neutropenia (<1×109/l). Other toxicity was frequent and included nausea/vomiting (80%), alopecia (95%) and stomatitis (35%). Five patients showed a significant fall in cardiac output, but this reverted to normal after treatment. Epirubicin should have a role in the development of high-dose regimens for the treatment of advanced breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM (1989) The use of granulocyte colony-stimulting factor to increaase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60: 121–125
Carmo-Pereira J, Costa FO, Henriques E, Godinho R, Cantinho-Lopes G, Sales-Luis A, Rubens RD (1987) A comparison of two doses of Adriamycon in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56: 471–473
Hayward JL, Rubens RD, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A (1977) Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292–298
Henderson C, Hayes D, Come S, Harris J, Canellos G (1987) New agents and new medical treatments for advanced breast cancer. Semin Oncol 14: 34–64
Hryniuk WM (1987) Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14: 65–74
Steiner R, Stewart J, Cantwell B, Minton M, Knight R, Rubens RD (1983) Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 19: 1553–1557
Tranum B, McDonald B, Thigpen T, Vaughan C, Wilson H, Maloney, Costanzi J, Bickers J, Gad el Mawli N, Palmer R, Hoogstraten E, Heilburn L, Rasmusen S (1982) Adriamycin combinations in advanced breast cancer. Cancer 49: 835–839
Van Oosterom AT, Anderson M, Wildiers J, Klijn J, Jassem J, Peridaens R, Rotmensz N, Sylvester R, Mouridsen H (1987) Adriamycin versus 4-Epi-adriamycin, report of a second-line randomised phase III study in advanced breast cancer (Trial 10 811) (abstract 436). Proceedings, 4th EORTC Breast Cancer Working Conference
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carmo-Pereira, J., Costa, F.O., Miles, D.W. et al. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study. Cancer Chemother. Pharmacol. 27, 394–396 (1991). https://doi.org/10.1007/BF00688864
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00688864